Navigation Links
Researchers Hunt Normal Cells That Give Rise to Cancer
Date:8/11/2008

Identifying these progenitors may provide context for tumor formation, new treatments

MONDAY, Aug. 11 (HealthDay News) -- Learning more about normal cells that give rise to cancer may hold the key to understanding and treating cancer, according to Duke University Medical Center researchers who identified cells linked to a deadly brain cancer.

"Identifying the specific, normal cells that cancer come from can provide critical insight into how cancers develop. This may help us develop more rational and effective approaches to treatment," Robert Wechsler-Reya, an associate professor of pharmacology and cancer biology, said in a medical center news release.

In what's believed to be a first, the Duke team had identified two types of cells in the brain that can give rise to the malignant brain tumor medulloblastoma. It occurs most commonly in children and is treated with a combination of surgery, chemotherapy and radiation, which cause severe side effects.

In order to identify the normal cells associated with medulloblastoma, the Duke researchers and colleagues in Australia created mouse models of medulloblastoma by turning off the patched gene, an important regulator of cell growth in the cerebellum. Specifically, they switched off the patched gene in granule neuron precursors (GNPs), which make one particular type of neuron, or in stem cells, which can make all the different cell types in the cerebellum.

When the patched gene was turned off in GNPs, 100 percent of the mice developed medulloblastoma. When the gene was deleted from stem cells, most of them went on to form normal cell types within the cerebellum.

The findings provide the first definitive proof that medulloblastoma can be triggered in GNPs, the researchers said.

"Simply mutating a gene is not enough to cause cancer. The mutation has to happen in the right cell type at the right time. In the case of patched, GNPs provide th
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Researchers to begin study aimed at helping Latino HIV patients
2. Researchers report periodontal disease independently predicts new onset diabetes
3. Researchers Find Genes That Influence West Nile Virus
4. Researchers unveil vital key to cancer
5. Researchers find differences in swallowing mechanism of Rett syndrome patients
6. Dartmouth researchers say too many children see extreme violence in movies
7. Penn researchers find a new role for a Foxy Old Gene
8. U of M researchers find cerebral malaria may be a major cause of brain injury in African children
9. Researchers Map Americas Deadliest Roads
10. Researchers disprove long-standing belief about HIV treatment
11. Teamwork cuts out unnecessary biopsies, researchers find

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...atches now available, many more to come, NIH direc...Day News) -- Thirteen stem cell lines have been a...yer-funded research, and many more such lines will...ounced Wednesday. , These are the first additio...h funded by the U.S. National Institutes of Health...
(Date:12/2/2009)... SAN FRANCISCO, Dec. 2 ...bies are born contaminated with a plastics chemica...ess must act immediately to protect infants and mo...bills to ban bisphenol A, or BPA, in food and beve...in of California and Rep. Edward Markey of Massach...
(Date:12/2/2009)..., MONTREAL, Dec. 2 /PRNewswire/ - As part of its c...world, Wyeth, now a part of Pfizer, has pledged mo...ctor concentrates to the World Federation of Hemop...e to the WFH,s Humanitarian Aid Program, and will ...ls. ,, "This donation will directly support bui...
(Date:12/2/2009)... , Ruling by federal government ends nine ... ANGELES, Dec. 2 More t...iser Permanente facilities across Southern Califor... National Union of Healthcare Workers (NUHW). ,...n NUHW in February, but SEIU delayed the election ...
(Date:12/2/2009)... MAJoseph Balboni loves sports. An avid tennis pla...ar-old insurance agent became increasingly frustra...conus, a degenerative eye disorder. Unable to retu...es, he faced the prospect of a corneal transplant ...ree years ago, Balboni discovered an alternative t...
Breaking Medicine News(10 mins):Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3Health News:Pre-Polluted Babies: Congress Must Act to Protect Infants, Moms from Toxic Plastics Chemical BPA 2Health News:The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH 2Health News:Labor Board OKs 2,300 Kaiser Professionals to Quit SEIU and Join National Union of Healthcare Workers 2Health News:Brandeis studies evaluate visionary approach to improving eyesight 2
...t our troops" is no longer just,a slogan -- it,s a...ND.org and a,new marketing campaign for the renam... pro bono support of JWT Atlanta., By focusing on...jured troops and their families and to ensure,that...
..., at the annual,research conference of the America... leading scientists discussed the state of the evi...cancer risk., Dietary supplements are a $22 billi...can be either protective or,harmful., The opening...
...Strategy for Invisicare Is Put In Place, LAS VEGA...SKVI), the developers of Invisicare, a patented po...ied products, today announced,the appointment of G...al markets. Dr. Cauwenbergh has vast,international...
... Last year, Mimi Avery of Texas learned her three...of a golf ball. A half-year earlier in Iowa, Peggy...d with the same rare form of cancer, called medull...t muscle tumor. , CHICAG...
...ogy, Inc. ("US Oncology" or,"the Company"), one of...es,reported revenue of $821.7 million, EBITDA of $...t income of $3.9 million and operating cash flow,o...ion, EBITDA of $(217.7) million, Adjusted EBITDA o...
...rimary Endpoints Achieved for SCOLR,s 12 Hour,Ibup...,(Amex: DDD ) today reported favorable top-line r...e the safety and efficacy of its 12 hour CDT(R),60...et both co-primary endpoints (p<0.0001), and h...
Other Medicine News:Health News:Bob Woodruff Foundation and JWT Introduce Marketing Campaign and Unveil www.ReMIND.org 2Health News:Bob Woodruff Foundation and JWT Introduce Marketing Campaign and Unveil www.ReMIND.org 3Health News:Scientists Debate Dietary Supplements and Cancer Risk at AICR Conference 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 3Health News: Three Women in Health Crises Go Online to Form Lifelong Friendships : Mothers of Boys with Cancer Find Support, Encouragement and Each Other at CarePages.com 2Health News: Three Women in Health Crises Go Online to Form Lifelong Friendships : Mothers of Boys with Cancer Find Support, Encouragement and Each Other at CarePages.com 3Health News:US Oncology Reports Third Quarter 2008 Results 2Health News:US Oncology Reports Third Quarter 2008 Results 3Health News:US Oncology Reports Third Quarter 2008 Results 4Health News:US Oncology Reports Third Quarter 2008 Results 5Health News:US Oncology Reports Third Quarter 2008 Results 6Health News:US Oncology Reports Third Quarter 2008 Results 7Health News:US Oncology Reports Third Quarter 2008 Results 8Health News:US Oncology Reports Third Quarter 2008 Results 9Health News:US Oncology Reports Third Quarter 2008 Results 10Health News:US Oncology Reports Third Quarter 2008 Results 11Health News:US Oncology Reports Third Quarter 2008 Results 12Health News:US Oncology Reports Third Quarter 2008 Results 13Health News:US Oncology Reports Third Quarter 2008 Results 14Health News:US Oncology Reports Third Quarter 2008 Results 15Health News:US Oncology Reports Third Quarter 2008 Results 16Health News:US Oncology Reports Third Quarter 2008 Results 17Health News:US Oncology Reports Third Quarter 2008 Results 18Health News:US Oncology Reports Third Quarter 2008 Results 19Health News:US Oncology Reports Third Quarter 2008 Results 20Health News:US Oncology Reports Third Quarter 2008 Results 21Health News:US Oncology Reports Third Quarter 2008 Results 22Health News:US Oncology Reports Third Quarter 2008 Results 23Health News:SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen 2Health News:SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen 3Health News:SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen 4
(Date:12/2/2009)..., , NANJING, China, Dec. 2 /PRNewsw...e" or the "Company") (NYSE: SCR ), a leading pha...t, manufacturing, and marketing of branded,generic...eported that its,subsidiary Jiangsu Yanshen Biolog...) has suspended production of all its products in ...
(Date:12/2/2009)..., , EAST HANOVER, N.J., Dec. 2 /PRN..., including a late-breaking presentation on Tasign...hronic myeloid leukemia, demonstrate the strength ... the care of patients. ,, The new data, at the...Meeting and Exposition, highlight the company,s cu...
(Date:12/1/2009)..., , TEMECULA, Calif., Dec. 1 /PRNewswire-Fi... Bulletin Board: PSTX) announced today that it has...of Chief Financial Officer, Treasurer and Corporat...cting CFO since 2008. Prior to joining Patient Sa...nt Finance, Chief Financial Officer, Treasurer and...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer 2Humans Can Develop Bat Like Echolocation 51093 1Humans Can Develop Bat Like Echolocation 51093 2Communicating science to decision makers 51089 1Omega 3s Benefit Heart Attack Survivors Healthy Adults Mothers and Infants 51086 1Omega 3s Benefit Heart Attack Survivors Healthy Adults Mothers and Infants 51086 2
...SS WIRE)--Jun 5, 2007 - Javelin,Pharmaceuticals, I...ucts for pain control, today announced that its Ph...n Pain Medicine, the,official journal of The Ameri...d, "Analgesic Efficacy and Safety of,Morphine-Chit...evere Pain Following Orthopedic Surgery", was rece...
...ta Presented at the , 2007 American Society of Cli...) Activity in Older Patients with AML and in,Refra...on of the molecular interaction of Aloxi(R),with ,...rvival Analysis of Glioblastoma Patients,Treated ,...cribed-- , --Survival Analysis of Irofulven in Sec...
Other Medicine Technology:Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine 2Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine 3MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 10
Right Dr. White Carina Hook
SHERIDAN LASER-TRACH Endotracheal Tubes
SHERIDAN LAR-A-JECT® Reinforced Laryngectomy Tubes
SPIRAL-FLEX® Reinforced Oral/Nasal Cuffed Endotracheal Tubes
Medicine Products: